We look at the prescription trends and take that as a great indicator for the unmet need for this condition. Chief Executive Flemming Ornskov More Quotes by Chief Executive Flemming Ornskov More Quotes From Chief Executive Flemming Ornskov This is a totally different scale and you need a bit more patience, you need a bit more time. In the end we will deliver the same outcome: we will pay off the debt and we will improve margins, the Street is wanting to see quarter-by-quarter that we can actually integrate this business, that we haven't over-stretched and can pay down debt. Chief Executive Flemming Ornskov health-news To make a comparison from Zydus to all the other ones, is I think a stretch of the imagination. Chief Executive Flemming Ornskov health-news We have invested beyond just the quarter (...) in growth for the full year and for the coming years, we actually upgraded EPS guidance for the year. I don't think you do that if you don't have increased confidence in your outlook and you have your expenses under full control. Chief Executive Flemming Ornskov company-news We have a strategy of becoming a leading global biotech company focused on rare disease and select other speciality areas and M&A small or large could be part of that. Chief Executive Flemming Ornskov company-news We are firing on all cylinders, we are very satisfied with the progress we've made. Chief Executive Flemming Ornskov healthcare The designation is normally given if a compound potentially would bring significant progress either in terms of safety or efficacy, so we take that as a positive sign. Chief Executive Flemming Ornskov healthcare We have excellent momentum and we are gaining even further momentum. Chief Executive Flemming Ornskov company-news
